| | Pfizer announced the M&A event of the year with its Biohaven acquisition. Top investors turned to Tegus for on-demand insight on Nurtec’s trajectory, Biohaven’s leadership, and the competitive environment. See for yourself with a free Tegus trial. |
Eli Lilly plots $2.1B manufacturing expansion at America's crossroads, with 500 new hires With failed COVID shot still dragging on earnings, CureVac tries to turn page to next-gen mRNA tech Advocate Aurora hit with class action alleging anticompetitive behavior in eastern Wisconsin Siemens Healthineers adds VR training for mobile 3D X-ray system with PrecisionOS collab Forte fields demand to liquidate from top shareholder who says latest asset came 'out of thin air' New Senate bill aims to empower FTC to crack down on PBMs Kadmon consultant charged with insider trading ahead of biotech's $1.9B sale to Sanofi: SEC RapidAI speeds up pulmonary embolism diagnosis with FDA clearance for AI triage tool Geisinger taps Amazon Web Services for cloud technology, AI and machine learning Teva, AbbVie's Allergan hand over $161M to settle opioid lawsuit in West Virginia Multiomics startup Pleno nabs $15M for a telecom-based approach to analyzing DNA, RNA Antios rocked as hepatitis B safety signal sparks clinical hold, termination of collaboration Featured Story | By Fraiser Kansteiner After socking $1 billion into a new injectables factory in North Carolina in January, Lilly is dipping back into its pocketbook for another blockbuster manufacturing expansion stateside. And this time, it’s reinvesting in its roots. read more |
| |
|---|
|
Top Stories By Annalee Armstrong CureVac’s so-called first generation COVID vaccine—a shot that failed to reach anywhere near the high efficacy bar set by rivals—is continuing to drag on the German biotech’s earnings, a break in the sails expected to stay around through the year. read more By Dave Muoio Plaintiffs alleged the 27-hospital nonprofit used its size to suppress competition and drive "unreasonably high prices" for payers, employers and taxpayers. read more By Andrea Park Using PrecisionOS’ technology—which is installed on Oculus VR headsets—surgeons and OR technicians will be able to complete practice sessions using Siemens' Cios Spin machine together, giving them the chance to share their expertise with one another and improve their collaboration in the operating room. read more By Max Bayer Forte Biosciences’ top shareholder is calling on the biotech to close up shop before it pours money into a brand new lead asset, saying the compound appears to have come “out of thin air.” read more By Robert King A new bipartisan bill aims to rein in several pharmacy benefit manager practices ranging from spread pricing to pharmacy clawback fees. read more By Fraiser Kansteiner The Securities and Exchange Commission has charged California-based executive compensation consultant Frank Glassner with insider trading, according to a complaint filed in a federal Manhattan court Tuesday. Glassner was a long-time consultant to Kadmon who was enlisted to provide acquisition-related services to the biotech, the SEC said in a release. Sanofi closed its $1.9 billion deal for the biotech in November. read more By Andrea Park RapidAI's software is designed to speed up the time it takes for physicians to identify a pulmonary embolism, confirm the diagnosis and begin treatment while also helping hospitals coordinate care and allot resources more efficiently. read more By Heather Landi Regional health system Geisinger tapped Amazon's cloud division as its strategic cloud tech provider and plans to transition its entire digital portfolio of more than 400 applications and numerous workflows to AWS. read more By Zoey Becker Teva and Allergan forked over $161 million to West Virginia to settle opioid litigation, including $27 million worth of Narcan. read more By Conor Hale The company claims its tech can simultaneously analyze DNA, RNA and methylation structures as well as the sample’s overall protein content. read more By Nick Paul Taylor Antios Therapeutics’ push to develop a curative hepatitis B therapy has hit turbulence. The FDA has hit Antios with a clinical hold over a safety report, prompting Assembly Biosciences to terminate its clinical trial collaboration agreement with the deep-pocketed biotech. read more |
